title: Are African American patients at a higher risk for olanzapine-induced glucose intolerance?
authors.forename: J
authors.initials: J
authors.lastname: Ananth
authors.forename: S
authors.initials: S
authors.lastname: Gunatilake
authors.forename: S
authors.initials: S
authors.lastname: Aquino
authors.forename: V
authors.initials: V
authors.lastname: Bach
authors.forename: J
authors.initials: J
authors.lastname: Costa
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D044383:Black People; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D012559:Schizophrenia / Q000150:complications; D044465:White People; D001741:Black or African American
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine